1. Academic Validation
  2. Osthole Reduces Mouse IOP Associated With Ameliorating Extracellular Matrix Expression of Trabecular Meshwork Cell

Osthole Reduces Mouse IOP Associated With Ameliorating Extracellular Matrix Expression of Trabecular Meshwork Cell

  • Invest Ophthalmol Vis Sci. 2020 Aug 3;61(10):38. doi: 10.1167/iovs.61.10.38.
Yuchen Fan 1 2 3 Jiahong Wei 4 Li Guo 5 Siyu Zhao 4 Chenyu Xu 4 Hao Sun 1 2 Tao Guo 1 2
Affiliations

Affiliations

  • 1 Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • 2 Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China.
  • 3 Department of Ophthalmology, the First Affiliated Hospital of Bengbu Medicine College, Bengbu, Anhui, China.
  • 4 Bengbu Medicine College, Bengbu, Anhui, China.
  • 5 Department of Ophthalmology, Luan Affiliated Hospital of Anhui Medicine University, Luan, Anhui, China.
Abstract

Purpose: Elevation of IOP in POAG is thought to involve excessive accumulation of extracellular matrix in the trabecular meshwork (TM), leading to an increase in outflow resistance of the aqueous humor. Osthole, a coumarin derivative extracted from the fruit of a variety of Plants, such as Cnidium monnieri, is reported to prevent profibrotic responses by inhibiting Smad signaling pathway activated by TGF-β in liver, kidney, and cardiac tissues. We tested if osthole can (1) inhibit TGF-β2-induced extracellular matrix expression in cultured human TM (HTM) cells, and (2) lower TGF-β2-induced ocular hypertension in the mouse.

Methods: Cultured HTM cells were treated with 5 ng/mL TGF-β2 for 48 hours, then with osthole for 24 hours. The expressions of fibronectin, collagen type IV, and laminin were assessed by quantitative PCR, Western blot, and immunocytochemistry. BALB/cJ mice were injected intravitreally with an adenoviral vector encoding a bioactive mutant of TGF-β2 (Ad.hTGF-β2226/228) in one eye to induce ocular hypertension, with the uninjected contralateral or Ad.Empty-injected eye serving as controls. Mice were then treated with a daily intraperitoneal injection of 30 mg/kg osthole. Conscious mouse IOP values were measured using a TonoLab rebound tonometer.

Results: In cultured HTM cells, stimulation with TGF-β2 increased expressions of fibronectin, collagen IV, and laminin. These in vitro changes were significantly and completely mitigated by osthole (10 µM). Daily intraperitoneal injections of 30 mg/kg osthole, starting either at day 0 (same day as Ad.hTGF-β2226/228 injection) or at day 14, significantly decreased TGF-β2-induced ocular hypertension in the mouse. In contrast, osthole did not affect IOP of control eyes.

Conclusions: These results demonstrated that osthole is capable of reducing TGF-β2-induced extracellular matrix expression in cultured HTM cells. It also reduced TGF-β2-induced ocular hypertension in the mouse. These findings indicate that this natural product may be useful as a novel treatment for POAG.

Figures
Products